AKTS 内幕交易
AKTS 的 SEC Form 4 内幕交易记录
总交易
90
买入
9
买入总额
$114.3M
卖出总额
$6.7M
| 信号 | 内幕人 | 职位 | 方向 | 股数 | 价格 | 金额 | 日期 | 信号原因 |
|---|---|---|---|---|---|---|---|---|
| ★★★★★(55) | KIM HELEN SUSAN | - | 买入 | 812,455 | $18.00 | $14.6M | 2026-01-12 | 董事买入, 大股东(>10%)买入 |
| ★★★★★(50) | FOLEY TODD | - | 买入 | 232,870 | $18.00 | $4.2M | 2026-01-12 | 董事买入, 大股东(>10%)买入 |
| ★★★★★(45) | RON-BIGGER SHULAMIT | Chief Operating Officer | 卖出 | 30,000 | $27.94 | $838K | 2026-07-08 | C-suite卖出, 大额卖出(>$500K) |
| ★★★★★(40) | RON-BIGGER SHULAMIT | Chief Operating Officer | 卖出 | 4,200 | $28.75 | $121K | 2026-07-08 | C-suite卖出, 非10b5-1计划卖出 |
| ★★★★★(40) | GADICKE ANSBERT | - | 买入 | 1,112,777 | $18.00 | $20.0M | 2026-01-12 | 大股东(>10%)买入, 超大额买入(>$5M) |
| ★★★★★(40) | MPM BIOVENTURES 2018, L.P. | - | 买入 | 1,112,777 | $18.00 | $20.0M | 2026-01-12 | 大股东(>10%)买入, 超大额买入(>$5M) |
| ★★★★★(40) | VIDA VENTURES II, LLC | - | 买入 | 812,455 | $18.00 | $14.6M | 2026-01-12 | 大股东(>10%)买入, 超大额买入(>$5M) |
| ★★★★★(40) | ECOR1 CAPITAL, LLC | - | 买入 | 2,077,779 | $18.00 | $37.4M | 2026-01-12 | 董事买入, 超大额买入(>$5M) |
| ★★★★★(40) | KIM HELEN SUSAN | - | 买入 | 22,545 | $18.00 | $406K | 2026-01-12 | 董事买入, 大股东(>10%)买入 |
| ★★★★★(38) | CZIBERE AKOS | Chief Medical Officer | 卖出 | 30,829 | $27.95 | $862K | 2026-07-08 | 高管卖出, 大额卖出(>$500K) |
| ★★★★★(35) | HERRMANN KEN | - | 卖出 | 1,350 | $24.56 | $33K | 2026-07-20 | 董事卖出, 非10b5-1计划卖出 |
| ★★★★★(35) | HERRMANN KEN | - | 卖出 | 3,506 | $24.56 | $86K | 2026-07-20 | 董事卖出, 非10b5-1计划卖出 |
| ★★★★★(35) | HERRMANN KEN | - | 卖出 | 3,065 | $25.21 | $77K | 2026-07-17 | 董事卖出, 非10b5-1计划卖出 |
| ★★★★★(35) | RON-BIGGER SHULAMIT | Chief Operating Officer | 卖出 | 50,000 | $27.75 | $1.4M | 2026-07-08 | C-suite卖出, 百万级卖出 |
| ★★★★★(35) | ECOR1 CAPITAL, LLC | - | 买入 | 144,443 | $18.00 | $2.6M | 2026-01-12 | 董事买入, 百万级买入 |
| ★★★★★(33) | RON-BIGGER SHULAMIT | Chief Operating Officer | 卖出 | 15,800 | $27.13 | $429K | 2026-07-08 | C-suite卖出, 非10b5-1计划卖出 |
| ★★★★★(33) | CZIBERE AKOS | Chief Medical Officer | 卖出 | 4,371 | $28.71 | $125K | 2026-07-08 | 高管卖出, 非10b5-1计划卖出 |
| ★★★★★(28) | CZIBERE AKOS | Chief Medical Officer | 卖出 | 50,000 | $27.77 | $1.4M | 2026-07-08 | 高管卖出, 百万级卖出 |
| ★★★★★(26) | CZIBERE AKOS | Chief Medical Officer | 卖出 | 14,800 | $27.13 | $402K | 2026-07-08 | 高管卖出, 非10b5-1计划卖出 |
| ★★★★★(25) | VIDA VENTURES II, LLC | - | 买入 | 22,545 | $18.00 | $406K | 2026-01-12 | 大股东(>10%)买入, 买入>$100K |
| ★★★★★(23) | CZIBERE AKOS | Chief Medical Officer | 卖出 | 7,401 | $21.03 | $156K | 2026-09-23 | 高管卖出, 减持超50%持仓 |
| ★★★★★(20) | HERRMANN KEN | - | 卖出 | 4,856 | $24.56 | $119K | 2026-07-20 | 董事卖出, 非10b5-1计划卖出 |
| ★★★★★(16) | CZIBERE AKOS | Chief Medical Officer | 卖出 | 5,099 | $20.19 | $103K | 2026-09-23 | 高管卖出, 减持超20%持仓 |
| ★★★★★(13) | CZIBERE AKOS | Chief Medical Officer | 卖出 | 25,000 | $22.11 | $553K | 2026-09-23 | 高管卖出, 大额卖出(>$500K) |
| ★★★★★(0) | CZIBERE AKOS | Chief Medical Officer | 卖出 | 12,500 | $4.95 | $62K | 2026-09-23 | |
| ★★★★★(0) | HERRMANN KEN | - | 卖出 | 1,350 | $1.91 | $3K | 2026-07-20 | |
| ★★★★★(0) | HERRMANN KEN | - | 卖出 | 3,506 | - | - | 2026-07-20 | |
| ★★★★★(0) | HERRMANN KEN | - | 卖出 | 3,065 | - | - | 2026-07-17 | |
| ★★★★★(0) | RON-BIGGER SHULAMIT | Chief Operating Officer | 卖出 | 50,000 | $3.66 | $183K | 2026-07-08 | |
| ★★★★★(0) | CZIBERE AKOS | Chief Medical Officer | 卖出 | 50,000 | - | - | 2026-07-08 | |
| ★★★★★(0) | GORMLEY GLENN | - | 卖出 | 37,866 | - | - | 2026-04-15 | |
| ★★★★★(0) | ELI LILLY & CO | - | 卖出 | 0 | - | - | 2026-01-12 | |
| ★★★★★(0) | MPM BIOVENTURES 2018, L.P. | - | 卖出 | 1,577,119 | - | - | 2026-01-12 | |
| ★★★★★(0) | MPM BIOVENTURES 2018, L.P. | - | 卖出 | 1,314,262 | - | - | 2026-01-12 | |
| ★★★★★(0) | FOLEY TODD | - | 卖出 | 2,727,273 | - | - | 2026-01-12 | |
| ★★★★★(0) | MPM BIOVENTURES 2018, L.P. | - | 卖出 | 5,914,197 | - | - | 2026-01-12 | |
| ★★★★★(0) | MPM BIOVENTURES 2018, L.P. | - | 卖出 | 5,000,000 | - | - | 2026-01-12 | |
| ★★★★★(0) | MPM BIOVENTURES 2018, L.P. | - | 卖出 | 22,500,000 | - | - | 2026-01-12 | |
| ★★★★★(0) | GADICKE ANSBERT | - | 卖出 | 6,000,000 | - | - | 2026-01-12 | |
| ★★★★★(0) | FOLEY TODD | - | 卖出 | 716,872 | - | - | 2026-01-12 | |
| ★★★★★(0) | GADICKE ANSBERT | - | 卖出 | 22,500,000 | - | - | 2026-01-12 | |
| ★★★★★(0) | GADICKE ANSBERT | - | 卖出 | 5,000,000 | - | - | 2026-01-12 | |
| ★★★★★(0) | FOLEY TODD | - | 卖出 | 2,688,270 | - | - | 2026-01-12 | |
| ★★★★★(0) | GADICKE ANSBERT | - | 卖出 | 1,314,262 | - | - | 2026-01-12 | |
| ★★★★★(0) | GADICKE ANSBERT | - | 卖出 | 1,577,119 | - | - | 2026-01-12 | |
| ★★★★★(0) | MPM BIOVENTURES 2018, L.P. | - | 卖出 | 6,000,000 | - | - | 2026-01-12 | |
| ★★★★★(0) | FOLEY TODD | - | 卖出 | 2,272,727 | - | - | 2026-01-12 | |
| ★★★★★(0) | FOLEY TODD | - | 卖出 | 10,227,273 | - | - | 2026-01-12 | |
| ★★★★★(0) | FOLEY TODD | - | 卖出 | 597,391 | - | - | 2026-01-12 | |
| ★★★★★(0) | GADICKE ANSBERT | - | 卖出 | 5,914,197 | - | - | 2026-01-12 | |
| ★★★★★(0) | ECOR1 CAPITAL, LLC | - | 卖出 | 997,299 | - | - | 2026-01-12 | |
| ★★★★★(0) | ECOR1 CAPITAL, LLC | - | 卖出 | 202,862 | - | - | 2026-01-12 | |
| ★★★★★(0) | ECOR1 CAPITAL, LLC | - | 卖出 | 2,270,879 | - | - | 2026-01-12 | |
| ★★★★★(0) | VIDA VENTURES II, LLC | - | 卖出 | 4,859,370 | - | - | 2026-01-12 | |
| ★★★★★(0) | VIDA VENTURES II, LLC | - | 卖出 | 134,842 | - | - | 2026-01-12 | |
| ★★★★★(0) | SEGAL LLOYD MITCHELL | - | 卖出 | 24,687 | - | - | 2026-01-12 | |
| ★★★★★(0) | ECOR1 CAPITAL, LLC | - | 卖出 | 102,500 | - | - | 2026-01-12 | |
| ★★★★★(0) | KIM HELEN SUSAN | - | 卖出 | 4,859,370 | - | - | 2026-01-12 | |
| ★★★★★(0) | KIM HELEN SUSAN | - | 卖出 | 411,750 | - | - | 2026-01-12 | |
| ★★★★★(0) | SEGAL LLOYD MITCHELL | - | 卖出 | 50,000 | - | - | 2026-01-12 | |
| ★★★★★(0) | VIDA VENTURES II, LLC | - | 卖出 | 14,838,250 | - | - | 2026-01-12 | |
| ★★★★★(0) | KIM HELEN SUSAN | - | 卖出 | 3,648,750 | - | - | 2026-01-12 | |
| ★★★★★(0) | ECOR1 CAPITAL, LLC | - | 卖出 | 86,222 | - | - | 2026-01-12 | |
| ★★★★★(0) | ECOR1 CAPITAL, LLC | - | 卖出 | 128,506 | - | - | 2026-01-12 | |
| ★★★★★(0) | VIDA VENTURES II, LLC | - | 卖出 | 3,648,750 | - | - | 2026-01-12 | |
| ★★★★★(0) | ECOR1 CAPITAL, LLC | - | 卖出 | 965,190 | - | - | 2026-01-12 | |
| ★★★★★(0) | KIM HELEN SUSAN | - | 卖出 | 101,250 | - | - | 2026-01-12 | |
| ★★★★★(0) | SEGAL LLOYD MITCHELL | - | 卖出 | 19,631 | - | - | 2026-01-12 | |
| ★★★★★(0) | KIM HELEN SUSAN | - | 卖出 | 134,842 | - | - | 2026-01-12 | |
| ★★★★★(0) | ECOR1 CAPITAL, LLC | - | 卖出 | 9,913,810 | - | - | 2026-01-12 | |
| ★★★★★(0) | ECOR1 CAPITAL, LLC | - | 卖出 | 488,891 | - | - | 2026-01-12 | |
| ★★★★★(0) | VIDA VENTURES II, LLC | - | 卖出 | 411,750 | - | - | 2026-01-12 | |
| ★★★★★(0) | KIM HELEN SUSAN | - | 卖出 | 14,838,250 | - | - | 2026-01-12 | |
| ★★★★★(0) | ECOR1 CAPITAL, LLC | - | 卖出 | 2,397,500 | - | - | 2026-01-12 | |
| ★★★★★(0) | VIDA VENTURES II, LLC | - | 卖出 | 101,250 | - | - | 2026-01-12 | |
| ★★★★★(0) | SHERMAN MICHAEL A. | - | 卖出 | 0 | - | - | 2026-01-08 | |
| ★★★★★(0) | THISTLE MARY | - | 卖出 | 0 | - | - | 2026-01-08 | |
| ★★★★★(0) | KIM HELEN SUSAN | - | 卖出 | 0 | - | - | 2026-01-08 | |
| ★★★★★(0) | GADICKE ANSBERT | - | 卖出 | 0 | - | - | 2026-01-08 | |
| ★★★★★(0) | HERRMANN KEN | - | 卖出 | 0 | - | - | 2026-01-08 | |
| ★★★★★(0) | RON-BIGGER SHULAMIT | Chief Operating Officer | 卖出 | 0 | - | - | 2026-01-08 | |
| ★★★★★(0) | SEGAL LLOYD MITCHELL | - | 卖出 | 0 | - | - | 2026-01-08 | |
| ★★★★★(0) | FOLEY TODD | - | 卖出 | 0 | - | - | 2026-01-08 | |
| ★★★★★(0) | VIDA VENTURES II, LLC | - | 卖出 | 0 | - | - | 2026-01-08 | |
| ★★★★★(0) | KUVALANKA KYLE D. | Chief Financial Officer | 卖出 | 0 | - | - | 2026-01-08 | |
| ★★★★★(0) | RODEN MATTHEW | President and CEO | 卖出 | 0 | - | - | 2026-01-08 | |
| ★★★★★(0) | CZIBERE AKOS | Chief Medical Officer | 卖出 | 0 | - | - | 2026-01-08 | |
| ★★★★★(0) | FELDMAN PAUL L | Chief Scientific Officer | 卖出 | 0 | - | - | 2026-01-08 | |
| ★★★★★(0) | ECOR1 CAPITAL, LLC | - | 卖出 | 0 | - | - | 2026-01-08 | |
| ★★★★★(0) | MPM BIOVENTURES 2018, L.P. | - | 卖出 | 0 | - | - | 2026-01-08 |